ArticleCureus2026
Central Diabetes Insipidus Following Steroid Replacement for Hypoadrenalism in Pembrolizumab-Induced Hypophysitis.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors are increasingly associated with complex immune-related endocrine adverse events that may evolve dynamically over time. We report a rare case of pembrolizumab-induced hypophysitis complicated by central diabetes insipidus, which was unmasked following glucocorticoid replacement. A 68-year-old female patient receiving immunotherapy for lung adenocarcinoma presented with hyponatremia and secondary adrenal insufficiency, followed by abrupt severe hypernatremia after steroid initiation. Subsequent evaluation confirmed central diabetes insipidus, and treatment with desmopressin resulted in clinical and biochemical recovery. This case highlights the diagnostic challenges posed by overlapping pituitary dysfunction and emphasizes the importance of dynamic endocrine reassessment when electrolyte disturbances evolve during immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.